38.59
+7.94%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Xencor
From its filings with the US Securities and Exchange Commission
Xencor is based in Pasadena, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker XNCR. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $125.6m and a net loss of $91.9m. At that date it held total assets of $875.5m and shareholders' equity of $635.6m.
We are a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases, who have unmet medical needs. We use our protein engineering capabilities to design new technologies and XmAb® drug candidates with improved properties and multi-target mechanisms of action. We advance these candidates into clinical-stage development, where we are conducting Phase 1 and Phase 2 studies for a broad portfolio of programs, to determine which programs to advance into later stages of development and potentially commercialization, which programs we partner to optimize development, and which programs we discontinue.
Our approach to protein design includes engineering Fc domains, the parts of antibodies that interact with multiple segments of the immune system and control antibody structure. The Fc domain is constant and interchangeable across antibodies, and our engineered Fc domains can be readily substituted for natural Fc domains. These Fc domains provide specific features such as bispecific structure and extended half-life and serve as the scaffolds for our XmAb drug candidates.
Quoted from its 10-K, filed 25 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 3 Dec 2013
- Employees
- 260
- Website
- xencor.com ↗
- Head office
- 465 N. HALSTEAD ST., PASADENA, CA, 91107
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Dr. Bassil DahiyatPresident, Chief Executive Officer, Founder and Director, since 1997$6.8m
- Mr. Bart CornelissenSenior Vice President, Chief Financial Officer$3.7m
- Dr. John DesjarlaisExecutive Vice President - Research, Chief Scientific Officer, since 2023$2.8m
- Ms. Celia EckertSenior Vice President, General Counsel, Corporate Secretary$2.0m
- Dr. A. Bruce MontgomeryLead Independent Director$372,899
- Dr. Raymond DeshaiesDirector
- Dr. Ellen FeigalIndependent Director$338,399
- Dr. Kevin GormanIndependent Director$332,899
- Mr. Kurt GustafsonIndependent Director$336,899
- Dr. Barbara KlenckeIndependent Director$324,399
- Mr. Richard RanieriIndependent Director$340,399
- Mr. Todd SimpsonIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 83
- Environment
- 90
- Social
- 83
- Governance
- 75
- Women in the workforce
- 59%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Xencor Inc possesses several key strengths that contribute to its success in the biopharmaceutical industry. These include:
Weaknesses
- Despite its strengths, Xencor Inc faces certain weaknesses that may hinder its growth and competitiveness:
Opportunities
- Xencor Inc has several opportunities for growth and expansion:
Threats
- Xencor Inc faces certain threats that could impact its operations and market position:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.